Chart-Typ:
Zeitraum:
| Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen |
| FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen |
| Novavax, Inc.: Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas
Multiple Material Transfer Agreements... ► Artikel lesen |
| Carbios: CARBIOS presents the results of its Annual General Meeting of June 18, 2026 | Clermont-Ferrand (France), June 22, 2026 (7:45 am CEST).
CARBIOS, (Euronext Growth Paris: ALCRB), announces the results of its Annual Ordinary and Extraordinary General Meeting held on June 18... ► Artikel lesen |
| CARBIOS presents the results of its Annual General Meeting of June 18, 2026 | Clermont-Ferrand (France), June 22, 2026 (7:45 am CEST). CARBIOS, (Euronext Growth Paris: ALCRB), announces the results of its Annual Ordinary and Extraordinary General Meeting held on June 18, 2026.... ► Artikel lesen |
| Update on the Carbios - Wankai project in China | Clermont-Ferrand (France), 2 June 2026 (05:45 pm CEST). Carbios (Euronext Growth Paris: ALCRB) provides an update on the progress of its strategic partnership with Wankai New Materials ("Wankai")... ► Artikel lesen |
| CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen |
| CRISPR Therapeutics-Aktie: Milliarden mit Gentherapie CASGEVY? | CRISPR Therapeutics vollzieht den Übergang von einem reinen Forschungsunternehmen zu einem kommerziellen Biotechnologieanbieter. Mit ersten nennenswerten Umsätzen und einer breiten Pipeline an innovativen... ► Artikel lesen |
| CRISPR Therapeutics AG: CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering | ZUG, Switzerland and BOSTON, March 11, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the "Company") today announced the pricing of $550 million aggregate principal amount of its... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OS THERAPIES INC finden Sie auf Wallstreet Online.